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A new approach based on targeted 
pooled DNA sequencing identifies 
novel mutations in patients with 
Inherited Retinal Dystrophies
Maitane Ezquerra-Inchausti1,2, Ander Anasagasti1, Olatz Barandika1, Gonzaga Garai-Aramburu3, 
Marta Galdós4, Adolfo López de Munain1,5,6,7, Cristina Irigoyen1,8 & Javier Ruiz-Ederra  1,2
Inherited retinal diseases (IRD) are a heterogeneous group of diseases that mainly affect the retina; 
more than 250 genes have been linked to the disease and more than 20 different clinical phenotypes 
have been described. This heterogeneity both at the clinical and genetic levels complicates the 
identification of causative mutations. Therefore, a detailed genetic characterization is important for 
genetic counselling and decisions regarding treatment. In this study, we developed a method consisting 
on pooled targeted next generation sequencing (NGS) that we applied to 316 eye disease related genes, 
followed by High Resolution Melting and copy number variation analysis. DNA from 115 unrelated test 
samples was pooled and samples with known mutations were used as positive controls to assess the 
sensitivity of our approach. Causal mutations for IRDs were found in 36 patients achieving a detection 
rate of 31.3%. Overall, 49 likely causative mutations were identified in characterized patients, 14 of 
which were first described in this study (28.6%). Our study shows that this new approach is a cost-
effective tool for detection of causative mutations in patients with inherited retinopathies.
Inherited retinal dystrophies (IRDs) are a group of heterogeneous diseases responsible for different clinically dis-
tinctive phenotypes. The most common IRD is Retinitis Pigmentosa (RP) with a prevalence of 1 in 3500 people. 
RP starts with night blindness and is followed by progressive loss of peripheral vision, leading to loss of central 
vision and blindness in most advanced cases. Although RP is clinically distinct from other IRDs, advanced stage 
of RP can be difficult to distinguish from other IRDs, including cone-rod or macular dystrophies1. Moreover, in 
some cases, clinical manifestations can differ among members of the same family. IRDs can be inherited in dif-
ferent traits including autosomal dominant (adRP), autosomal recessive (arRP) or X-linked (XlRP). The rate of 
inheritance has varied across populations studied. To date, over 250 genes have been related to various IRDs and 
some of them are responsible for the different phenotypes observed2 (https://sph.uth.edu/retnet/sum-dis.htm, 3 
July 2017).
Since the publication of the first draft of the human genome in 20013,4, we have seen an unprecedented flour-
ishing of sequencing technologies that provide genomic information in an accurate, fast and cost-efficient way. 
Methods of massive parallel sequencing such as targeted Next Generation Sequencing technologies (NGS) and 
Whole Exome Sequencing (WES) are the most widely used methods for the diagnosis of IRD. These methods have 
contributed to an exponential reduction in time and costs for the execution of the sequencing5,6. Nevertheless, the 
use of whole genome sequencing for diagnostic purposes is limited, mainly by the amount of data generated, which 
demands high degree of expertise in terms of big data handling and interpretation of the results, and these factors 
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complicate its transfer to the clinicians and to the patients. Comprehensive sequencing of the coding regions of 
all genes (Whole Exome Sequencing or WES) is more affordable, but still has high technical requirements that 
are an obstacle to its use as a diagnostic method in routine clinical practice. A more practical approach for clinical 
diagnosis may consist of an initial genetic screening of a subset of genes associated with a phenotype using targeted 
NGS, followed by a second more extensive genome analysis, such as WES6, and the analysis of the copy number 
variations (CNVs)1, for challenging cases for which the first strategy fails to indicate any genetic explanation.
In this study, we sequenced 316 genes associated with IRDs including several syndromic retinopathies. 
Targeted NGS typically involves a DNA-barcode labelling of each of the individuals to be sequenced for gen-
otyping purposes, this processing being a bottleneck process in terms of consumables, equipment and human 
resources. In order to simplify the sequencing process and to reduce the costs associated with individual labelling 
of DNA samples, we have developed a mutation detection approach based on targeted NGS in combination with 
high resolution melting (HRM) analysis. NGS was performed using pools of 16 DNA samples per pool, and 
identification of the sample/s carrying the mutation/s was performed using HRM analysis in individual samples, 
which allowed us to link mutations found in the pooled DNA samples to the DNA from individual patients. We 
sequenced samples from a total of 115 unrelated patients and 13 controls, 5 of which corresponded to samples 
from patients with IRD characterized by a third party laboratory. Information regarding mutations in these five 
controls was not revealed to us until completion of our analysis, to further test the sensitivity of our method in 
an objective way.
For those samples with negative results after the sequencing process, we used multiplex ligation-dependent 
probe amplification (MLPA) method for CNV analysis. After combining our sequencing strategy with MLPA, we 
were able to conclusively identify mutations in 36 patients, meaning that a genetic diagnosis rate was obtained in 
31.3% of cases.
Results
Targeted Sequencing. A total of 316 genes (Supplementary Table S1) divided into 7222 amplicons were 
analysed. A total of 2864 and 3350 genetic variants were found in the 4 and 8 sample pools, respectively, while 
3997 +/− 58 variants found in the 7 pools with 16 samples. Mean and median read depth obtained per sample 
were 196X and 193X, respectively. Less than 3.4% of targeted regions were covered less than 30X per pool, which 
we established as the cut off.
Sensitivity. In order to assess the sensitivity of our method we performed two independent experiments. In 
the first experiment, we included a set of 3 pools all containing an increasing number of control samples prepared 
from DNA from 16 patients (see methodology section and Supplementary Fig. S1 for a more detailed descrip-
tion). Each control sample carried at least one mutation that had been previously validated by Sanger sequencing 
(see methodology section). As a result, previously characterized mutations from all control samples were identi-
fied in the first set of samples, regardless of the size of the pool.
Following our method, one would expect a relative level of coverage of 1/32 in heterozygous variants and 
2/32 in one homozygous or in two heterozygous variants. However, we found that the number did not fit 
exactly to these values when analysing variants among solved patients (see variants in Table 1). Thus, in het-
erozygous variants the relative coverage ranged between 0.56 to 1.54/32 with 5 outliers with relative coverage 
of 1.75/32, 1.88/32, 1.99/32, 1.93/32 and 2/32, with values more suggestive of mutations present in two alleles 
rather than in one.
With respect to variants expected to be in two alleles (in homozygosis in one patient or in heterozygosis in two 
patients), the relative coverage ranged between 1.5–2.3/32. In this case we found 4 outliers with relative levels of 
coverage as low as 1.25/32 (2 cases), or as high as 2.98/32 and 3.13/32. In all cases with a higher relative coverage, 
in relation with the number of alleles found, all the pool was Sanger sequenced individually, in order to test for 
the presence of another allele with that variant and we found that there were no more alleles with the mutation 
among the pool.
Moreover, we tested 9 SNPs with higher MAFs in order to assess if the relative level of coverage was the same 
in the case of having more alleles with a specific SNP within the pool. All 16 samples from the pool in which 
the SNP was found, were directly Sanger sequenced. Similarly to what we observed in the candidate variants, 
we found some variability between expected vs. sequenced SNPs, with a slight mismatch of the variants present 
according to expected values (Supplementary Table S2).
Variant Identification. Once we established 16 as the most cost-effective sample size, we sequenced 7 pools 
of 16 samples/each, including a set of 19 different controls carrying a total of 21 previously detected rare (MAF < 
0.003), non-causative variants (control variants). All variants selected had a MAF < 0.003 for genes mainly asso-
ciated with a recessive inheritance pattern and were absent from the databases in the case of genes associated with 
a dominant inheritance pattern (Supplementary Table S3). As a result, all 21 control variants were also redetected. 
In both sets of experiments our methodology yielded 100% sensitivity.
Furthermore, we included five samples from patients with IRD provided by a third party laboratory. As infor-
mation about mutations within these samples was not initially disclosed to us, we were able to use these samples 
as an additional way to test the sensitivity of our method. We succeeded in identifying causal mutations in all 
of the samples. These were: a homozygous mutation c.1645G>T (p.Glu549Ter) in the BBS1 gene; c.1040C>A 
(p.Pro347Gln) mutation in the RHO gene; c.1703TA (p.Leu568Ter) mutation in the CHM gene; c.2888_2888del 
(p.Gly963fs) and c.3386G>T (p.Arg1129Leu) mutations in the ABCA4 gene and a homozygous mutation, 
c.397C>T (p.His133Tyr) in MYO7A gene.
With regard to the 115 unrelated patients analysed, disease causing mutations were found in at least one allele 
in 61 patients. Nevertheless, since in some patients, mutations were found only in one allele in recessive genes, 
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causal mutations were found in 36 patients, reaching a detection rate of 31.3% (Tables 1, 2 and Supplementary 
Fig. S2). Most of the pathogenic mutations were found in the USH2A gene, although in many cases only in one 
allele without a second mutation, and therefore in these recessive cases, we could not determine the causal muta-
tion. Among all mutations found in characterized patients, 15 were novel, 2 missense and 13 loss-of-function 
(LOF) mutations. Novel missense and splicing variant mutations were potentially pathogenic, this being inferred 
from the score obtained from different in-silico tools and the fact that they co-segregated with the disease 
(Supplementary Table S4).
Regarding the distribution of mutations among our cohort of patients, most findings were found among the 
following five genes:
USH2A. Mutations within this gene were responsible for most cases of arRP in our cohort. Most of the patients 
were carriers of biallelic mutations. Compound heterozygous mutations are frequently reported in this gene7,8. 
Four of the mutations found in USH2A were novel: c.11241C>G, in patient RP15, c.3669del in patient RP91, 
Family Gene Gene transcript
Allele1 Allele2 Family 
segregationcDNA Change Protein change Reference cDNA Change Protein change Reference
RP1 EYS NM_001142800 c.9405T>A p.Tyr3135Ter 11 c.1830del p.His610GlnfsTer26 This study Yes
RP8 CERKL NM_001030311.2 c.847C>T p.Arg283Ter 10 c.847C>T p.Arg283Ter 10 Yes
RP15 USH2A NM_206933 c.12093del p.Tyr4031Ter 8 c.11241C>G p.Tyr3747Ter This study Yes
RP17 CHM NM_000390 c.1272_1273delinsCT p.Gln425Ter 41 Yes
RP27 RPGR NM_001034853 c.2232_2235del p.Asp744GlufsTer70 This study Yes
RP34 USH2A NM_206933 c.2276G>T p.Cys759Phe 56 c.5278del p.Asp1760MetfsTer10
8 Yes
RP35 RP1 NM_006269 c.4804C>T p.Gln1602Ter 67 c.1837dup p.Thr613AsnfsTer6 This study Yes
RP49 EYS NM_001142800 c.4045C>T p.Arg1349Ter 12 c.4045C>T p.Arg1349Ter 12 Yes
RP57 TULP1 NM_003322 c.1495 + 1G>C 68 c.1495 + 1G>C 68 Yes
RP59 MYO7A NM_000260 c.1200G>T p.Lys400Asn 69 c.5074C>T p.Gln1692Ter This study N/A
RP77 CNGA1 NM_001142564 c.301C>T p.Arg101Ter 70 c.1747C>T p.Arg583Ter This study Yes
RP88 MYO7A NM_000260 c.3763del p.Lys1255ArgfsTer8 71 c.6_9dup p.Leu4AspfsTer39 This study Yes
RP91 USH2A NM_206933 c.11754G>A p.Trp3918Ter 72 c.3669del p.Cys1223Ter This study Yes
RP106 EYS NM_001142800 c.14C>A p.Ser5Ter This study c.888del p.Lys296AsnfsTer43 This study Yes
RP117 EYS NM_001142800 c.4045C>T p.Arg1349Ter 12 c.9405T>A p.Tyr3135Ter 11 Yes
RP153 CERKL NM_001030311.2 c.847C>T p.Arg283Ter 10 c.847C>T p.Arg283Ter 10 Yes
RP154 CNGA3 NM_001298 c.162_163insT p.Arg55Ter This study c.162_163insT p.Arg55Ter This study Yes
RP165 ABCA4 NM_000350 c.3322C>T p.Arg1108Cys 73 c.3322C>T p.Arg1108Cys 73 Yes
RP67 CERKL NM_001030311.2 c.847C>T p.Arg283Ter 10 c.847C>T p.Arg283Ter 10 Yes
RP109 USH2A NM_206933 c.1570G>A p.Ala524Val This study c.2276G>T p.Cys759Phe 56 Yes
RP141 USH2A NM_206933 c.2276G>T p.Cys759Phe 56 c.2299del p.Glu767SerfsTer21 74 Yes
RP173 NR2E3 NM_014249 c.932G>A p.Arg311Gln 75 c.932G>A p.Arg311Gln 75 N/A
RP174 RGR NM_001012720 c.196A>C p.Ser66Arg 76 c.196A>C p.Ser66Arg 76 Yes
RP175 CNGB3 NM_019098 c.1148del p.Thr383IlefsTer13 77 c.852 + 1G>C This study Yes
RP176 CERKL NM_001030311.2 c.847C>T p.Arg283Ter 10 c.847C>T p.Arg283Ter 10 Yes
RP180 USH2A NM_206933 c.14565del p.Asn4856MetfsTer28 This study c.14565del
p.
Asn4856MetfsTer28 This study Yes
RP182 PDE6A NM_000440 c.1957C>T p.Arg653Ter 78 c.1705C>A p.Gln569Lys 79 Yes
RP185 CNGA3 NM_001298 c.1228C>T p.Arg410Trp 80 c.829C>G p.Arg277Gly 81 Yes
RP196 BBS1 NM_024649 c.1220T>G p.Met390Arg 82 c.1220T>G p.Met390Arg 82 Yes
RP166 USH2A NM_206933 c.14091del p.Phe4697LeufsTer2 7 c.12093del p.Tyr4031Ter 8 N/A
RP169 CERKL NM_001030311.2 c.847C>T p.Arg283Ter 10 c.356G>A p.Gly119Asp 83 N/A
RP30 RP1 NM_006269 c.1625C>G p.Ser542Ter 84 c.227T>C p.Leu76Pro This study Yes
RP193 ABCA4 NM_000350 c.4577C>T p.Thr1526Met 36,85 c.3386G>T p.Arg1129Leu 86 N/A
RP200 CRB1 NM_201253 c.444_452del p.Asp148_Asp150del 87 c.2843G>A p.Cys948Tyr 88 Yes
RP188 CNGA3 NM_001298 c.1228C>T p.Arg410Trp 80 c.1706G>A p.Arg569His 81 N/A
RP40 PRPF31 NM_015629 exons9_13deletion This study Yes
RP148 PRPF8 NM_006445 c.6835T>G p.Trp2279Gly This study
RP181 PRPF31 NM_015629 c.1165C>T p.Gln389Ter This study No
RP92 PCDH15 CDH23
NM_001142763/ 
NM_022124 c.733C>T p.Arg245Ter
89 c.8326G>A p.Gly2776Ser This Study Yes
Table 1. Summary of all identified variants. Variants of uncertain significance (VUS) are in italics.
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c.1570G>A in patient RP109 and c.14565del in patient RP180. Except for patient RP180, homozygote carrier of 
the mutation, the rest of the patients were carriers of mutations in compound heterozygosis with the previously 
reported pathogenic mutations c.12093del, c.11754G>A and c.2276G>T respectively (Table 1).
Family
Age at 
diagnosis
Symptoms at 
diagnosis
Visual 
Acuity in 
LogMAR 
RE
Visual 
Acuity in 
LogMAR 
LE
Spherical 
Equivalent 
RE
Spherical 
Equivalent 
LE
Subcapsular 
Cataract 
(Yes, No 
Pseudo­
phakic) Pale disc
Arteriolar 
Attenuation
Bone 
Spicule 
Retinal 
Pigment
Epiretinal 
Membrane
Macular 
Edema
Visual 
Fields 
(grades)
ERG (Elect­
roretinogram)
Syndro­
mic RP
Family 
member 
affected 
(including 
case study)
RP1 20 Photophobia 2 0.8 −2.2 −2.62 PP Yes Yes Yes No No No, Low Vision Ext No 1
RP8 17 Nyctalopia 5 5 N/A N/A PP Yes Yes Yes Yes Yes No, Low Vision Ext No 1
RP15 23 Nyctalopia 0.4 0.3 −0.12 −0.62 PP Yes Yes Yes Yes No 4 N/A No 1
RP17 26 Nyctalopia 0.7 0.1 −6.5 −5.37 No Yes Yes No Yes Yes 4 Ext No 2
RP27 8 Decrease VA 3 3 0.12 −0.5 PP Yes Yes Yes No No No, Low Vision Ext No 3
RP30 26 Nyctalopia 0.7 0.7 −5.5 −5.25 Yes Yes Yes Yes No No Altered Ext No 1
RP34 37 Visual Field Loss 0.3 0.8 −0.5 −0.62 PP Yes Yes Yes No Yes 8 Ext No 1
RP35 5 Decrease VA 0.8 1,3 0 −0.25 PP Yes Yes Yes Yes Yes Altered Ext No 1
RP40 8 Nyctalopia 0 0 0 −0.75 No Yes Yes Yes No No 18 Ext No 2
RP49 16 Nyctalopia 0.4 0.5 0.87 0.75 Yes Yes Yes Yes Yes Yes 15 Ext No 1
RP57 9 Nyctalopia 1.3 4 13 2 PP Yes Yes Yes No No No, Low Vision Ext No 1
RP59 12 Nyctalopia 0 0 1.625 −1.25 No Yes Yes No No No 7 Ext Usher type 1 1
RP67 50 Decrease VA N/A N/A 2 0.75 Yes Yes Yes Yes No No No, Low vision Ext No 2
RP77 40 Nyctalopia 0.3 0.2 0.75 0.62 PP Yes Yes Yes Yes Yes 4 Ext No 2
RP88 12 Visual Field Loss 1.3 1 N/A N/A PP Yes Yes Yes No No
N/A, 
deafness Ext
Usher 
type 1 2
RP91 16 Nyctalopia 0.3 0.4 −1.62 −1.87 Yes Yes Yes Yes No No 8 Ext Usher 1
RP106 45 Nyctalopia 4 4 −8.75 −9.5 Yes Yes Yes Yes Yes NO No, Low Vision Ext No 1
RP117 27 Decrease VA 0.5 0.4 1.12 −1.5 No Yes Yes Yes No Yes 10 Ext No 4
RP141 35 Nyctalopia N/A N/A 1 1 Yes Yes Yes Yes No No N/A Ext No 1
RP153 17 Decrease VA 3 1 −0.5 −0.25 Yes Yes Yes Yes No No No, Low Vision N/A No 2
RP154 1 Decrease VA 1 1 3 1 No No No No No No Central Scotoma N/A Achrom. 2
RP165 17 Decrease VA 3 3 N/A N/A Yes Yes Yes Yes No No No, Low Vision Ext No 5
RP166 N/A Nyctalopia 0.2 0.3 −1 −1.75 Yes Yes Yes Yes No No 7 Ext Usher Type 2 1
RP169 31 Nyctalopia 5 4 N/A N/A Yes Yes Yes Yes No No No, Low Vision Ext No 2
RP173 1 Nyctalopia 1 1 −2 −0.25 No No No Yes No Yes No, Low Vision Ext No 2
RP174 38 Decrease VA 4 4 −3.37 −0.75 No Yes Yes Yes No No No, Low Vision Ext No 1
RP175 4 Decrease VA 1 1 −0.75 −0.125 No No No No No No No, Low Vision *1 Achrom. 2
RP176 22 Decrease VA 0.3 0.4 −0.75 −1.5 Yes Yes Yes Yes No No Central scotoma Ext No 1
RP180 38 Nyctalopia 4 4 N/A N/A Yes Yes Yes Yes No No No, Low Vision Ext
Usher 
Type 2 3
RP109 36 Nyctalopia 0.4 0.3 −0.5 0 Yes Yes Yes No Yes Yes 7 Ext No 1
RP182 10 Nyctalopia 0.05 0.05 −1.75 −1.25 Yes Yes Yes Yes No No 5 Ext No 1
RP185 1 Nystagmus 1.3 1.3 −5.37 −5.37 No No No No No No No, Low Vision *1 Achrom. 1
RP196 12 Decrease VA 1 1 −1.12 −2.12 Yes Yes Yes Yes No No 4 Ext No 1
RP200 31 Decrease VA 0.7 3 +0.75 +1.87 No Yes Yes No No No No, Low Vision Ext No 1
RP188 49 Decrease VA 0.8 1 +7.3 +7.3 No No No No No No No, Low visión C.R Ext No 1
RP193 38 Decrease VA 1 1 +2.62 +2.61 No No No No No No
No, 
Central 
Scotoma
N/A No 1
Table 2. Clinical features of characterized patients. Abbreviations; LE: Left eye; NA: not available; PP: 
Pseudophakia; RE: Right Eye; VA: Visual Acuity. *ERG not detected either in photopic nor escotopic 
conditions.
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CERKL. This was the second most commonly mutated gene in our cohort. We characterized 5 patients with the 
same mutation c.847C>T in this gene. In 4 of the cases it was in homozygosis and in one case it was in compound 
heterozygosis with c.356G>A mutation. This nonsense mutation is relatively common in Spanish cohorts9,10.
EYS. This was the third most commonly mutated gene in our cohort. Three out of four patients shared muta-
tions, such as RP1 and RP117 with c.9405T>A11 and RP49 and RP117 with c.4045T>A12, probably indicating 
the sharing of a common ancestor. This finding is consistent with previous studies involving Spanish cohorts, 
in which EYS was one of the most commonly mutated genes in recessive retinitis pigmentosa13,14. In addition, 
we found three novel mutations in this gene: two frameshift mutations in compound heterozygosis c.1830del in 
patient RP1 and c.888del in patient RP106; and a nonsense mutation also in compound heterozygosis c.14C>A, 
in patient RP106.
RPGR. We were able to detect a novel mutation c.2232_2235del in patient RP27 in the ORF15 region of this 
gene. Mutations in this region are challenging to amplify due to a large segment of highly repetitive purine-rich 
sequences15. Nevertheless, the high coverage of this region we obtained using our pooled-based approach, allowed 
us to detect this variant (Supplementary Fig. S3).
Variants of Uncertain Significance (VUS). For the family RP92, two heterozygous variants were 
observed in PCDH15 and CDH23. Despite the fact that this digenic inheritance pattern has previously been found 
to be causative of Usher Syndrome16, and that the variants segregated correctly within our family, there is some 
controversy with the pathogenicity of this digenism and, as far as we know, the CDH23 and PCDH15 digenism 
has been only reported in one study16. Despite cochlear degeneration specific to hair cells was observed in this 
type of mice, USH mutant mice do not display visual defects. Based on ultrastructural analyses, it has been shown 
that the USH1 proteins localize at the level of microvilli-like structures, called calyceal processes, which form a 
collar around the base of photoreceptor outer segments. These structures have only been found in primate and 
other large mammals, but not in mouse photoreceptor cells17. This has led to propose that the absence of these 
structures in the mouse retina is responsible for the lack of a visual phenotype in mouse models of Usher syn-
drome. Regardless of this structural difference, we cannot confirm that this digenism is the causative mutation.
In the case of family RP148, a novel missense mutation c.6835T>G was found in PRPF8 gene. The muta-
tion was predicted to be damaging by at least 5 in silico predictors. Nevertheless, given the lack of a complete 
segregation analysis due to the unavailability of many of the samples required, we were unable to conclude that 
c.6835T>G is the causal adRP mutation in this family. Similarly, in family RP181, we found a novel nonsense 
mutation, c.1165C>T, in PRPF31 gene. However we were not able to validate this finding in a segregation analysis 
due to a lack of samples available. In fact, the only family sample we were able to study was a non-affected sister 
who was also a mutation carrier.
Multiplex Ligation-dependent Probe Amplification (MLPA). Among the 32 families analysed by this 
method, we detected a large deletion in the PRPF31 gene expanding from exon 9 to 13 in family RP40, previ-
ously unreported. The deletion was also detected in an affected grandmother and the asymptomatic mother. 
Confirmation of the deletion region was performed sequencing the deleted DNA fragment (Fig. 1A).
Discussion
In the present work, we have developed a cost-effective method for the diagnosis of IRDs based on pooled 
genomic DNA targeted NGS, in combination with HRM as a highly sensitive, versatile and affordable genotyp-
ing method. Following our methodology, we were able to find the causal mutation in 36 of our patients (31.3%) 
(Table 1).
Several studies have validated the feasibility of DNA sequencing pools to identify and quantify the genetic 
variants or single nucleotide polymorphisms (SNPs) in small genomes or small genomic regions of prokaryotes18; 
and single human genes19,20. Previous studies tested experimentally the accuracy in re-sequencing pools of strains 
of highly isogenic D. melanogaster, whose genome had been previously sequenced individually. They showed that 
the sequenced pool provides a correct estimate of the population allele frequency, enabling the discovery of new 
SNPs with a low rate of false positives21.
Regarding clinical applications22 evaluated the use of pooled DNA sequencing to accurately assess allele fre-
quencies on transmitted and non-transmitted chromosomes in a set of families in an allelic association study23 
combined DNA samples from 1,111 individuals and sequenced 4 genes to identify rare germline variants. The 
main bottleneck in the use of a pooling strategy for genetic studies is related to the challenges of detecting rare 
and low-frequency variants reliably, allowing an accurate estimation of MAFs24. Moreover, pooled DNA sequenc-
ing was applied for the analysis of 3 genes of Gitelman’s syndrome using semiconductor NGS in pooled DNA 
samples from 20 patients25. In a more recent study, 72 genes were analysed in pools consisting of samples from 
12 individuals26. With respect to RP, pooled DNA NGS was used to search for mutations in the SNRNP200 gene 
in a cohort of 96 unrelated patients from North America27. Pooled DNA sequencing has recently been used for 
population genetics studies (GWAS), in several different pathologies28.
Compared to previous studies that limited to the sequencing of a restricted number of genes, this represents 
the first study based on the pooled sequencing of more than 300 genes. To estimate the reduction in costs derived 
from the use of our methodology we compared the costs per patient of our pooled method with an individual 
sequencing approach. The main source of cost savings was related to expenses involved in the preparation of DNA 
libraries. Specifically, there was a 10.6-fold reduction in sequencing costs with our methodology. Once we added 
costs associated with the HRM analysis-based genotyping method, the overall reduction in mutation detection/
patient was 6.25-fold.
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The choice of 16-sample pools was based, not only on terms of sensitivity, but also on the optimal number 
of samples for further analysis by HRM, which we found to be around 16 in a previous study29. One of the 
main advantages over previous pooled-NGS-based strategies for mutations detection is the genotyping method 
we used. HRM analysis is significantly more affordable than other methods including TaqMan probes (Thermo 
Fisher Scientific) especially if used for a large cohort of patients and/or for a large number of genes30; or DNA 
arrays Sequenom IPLEX (CD Genomics), which requires specific equipment, making the applicability of the 
methodology highly dependent on the equipment available in each laboratory30.
In order to test the sensitivity of our method we included a set of positive controls. Five of these positive con-
trols were samples from IRD patients previously diagnosed elsewhere, for whom we only had access to their clin-
ical data, but not to information on the causative mutations. Given that we obtained a sensitivity of 100%, the fact 
that our detection rate is not as high as in previous studies, ranging from 51 to 66%31–34, might be explained, at 
least in part, by the nature of the cohort of patients included in our study, since over half of our cohort of patients 
(69/115) were analysed in previous studies with no results, using a repertoire of different approaches9,29,35.
Therefore, we believe that the great number of samples analysed in previous studies is the main factor for the 
relative low yield obtained. A similar observation was recently reported, where they found that the patients who 
were screened for the first time had a higher pathogenic variant detection rate than the overall rate, suggesting 
that their cohort was enriched for intractable cases giving a lower detection rate36.
Another possibility is that the detection rate varies depending on the ethnicity of the individuals analysed36. In 
this regard, they reported a lower rate of homozygous variants detected in individuals of European origin, com-
paring with other populations, in recessive transmitted diseases36. Similarly, we found heterozygous mutations 
in recessive genes in 25 patients, which therefore cannot be regarded as the causal mutation on their own. One 
possibility is that a fraction of our patients might be bearing large DNA re-arrangements, or mutations in deep 
intronic regions not covered by our approach, which would act in compound heterozygosis.
One limitation of the approach used in this work was that the relative level of coverage expected in validated 
variants (1/32 in heterozygous variants and 2/32 in one homozygous or in two heterozygous variants) did not fit 
exactly to expected values in some cases (see Results section and supplementary Table S2). This could be due to 
the fact that there is a pre-amplification step for library preparation. Despite great care was taken for preparing 
the pools using equimolar amounts of each DNA sample, we cannot discard the possibility of having some sam-
ples over or under-represented, offering higher or lower relative values, respectively. This might be reflecting an 
unequal sample bias, or that all DNAs of each pool were not amplified in all regions, which might be one of the 
potential explanations for the relative low diagnostic yield. However, we consider this possibility unlikely, consid-
ering that we were able to detect all control variants introduced in each pool.
Another limitation of pooled sequencing method is related to the lack of use of multiplex barcodes, which 
complicates CNV detection using NGS technology37.
There is increasing evidence of genomic rearrangements resulting in CNVs responsible for IRDs in several 
genes including PRPF3138; EYS39; USH2A40 and X-linked RPGR and CHM41,42. Several recent studies have empha-
sized the importance of CNV analysis in IRD cases. For instance, Bujakowska et al.43 found mutations in 5 out 
Figure 1. Novel deletion in PRPF31. (A) Electropherogram showing a reduced dosage of exons 9–13 (arrows) 
in patient RP40. (B) Schematic representation of PRPF31 deletions described in the literature, and the deletion 
of exons 9–13 we found in this study, represented by the red bar. Abbreviations: P: control probes; Ex: Exon.
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of 28 IRD cases in SNRNP200, PRPF31, EYS and OPN1LW genes. Khateb et al.44; identified rearrangements in 
6 IRD patients out of 60 involving EYS, MYO7A, NPHP4, RPGR and CHM. This last case CHM was deleted in 
conjunction with other 6 genes. Van Cauwenbergh et al., 20161 identified CNV in 3 patients out of 57 analysed, 
with mutations in USH2A, HGSNAT and RCBTB1 genes. Interestingly, a recent paper has established a ranking of 
IRD genes according to genomic features and CNV occurrence. These authors recommend performing routinely 
a targeted CNV screening in the most prevalent 30 top-ranked IRD genes according to their genomic length45.
Despite some authors have described the use of read depth methods for pooled multiple sequencing46, we 
decided to select a group of 9 genes, most of which known to be prone to CNV formation45 using MLPA. We 
analysed several patients with negative results after the sequencing of the 316 IRD genes, and we included some 
of the genes reported as the main contributors to CNV in different studies, such as USH2A, EYS, CHM, PRPF31 
and RPGR1,38,43,44,47,48.
Using this approach, we were able to diagnose a patient with a deletion expanding from exon 9 to 13 in 
PRPF31. Rearrangements in this gene have been described to account for around 2.5% in autosomal dominant 
cases38. Although different mutated regions have been described in PRPF31, the deletion of exons 9 to 13 has not 
been described before (Fig. 1B).
The pattern of inheritance in family 40 is suggestive of an autosomal dominant pattern with incomplete pene-
trance. Segregation analysis was conducted in two family members, revealing the presence of an obligate carrier. 
Mutations in PRPF31 have been mostly associated with cases of incomplete penetrance49–51.
A limitation inherent to the technique employed, which is shared by WES, is the impossibility of finding muta-
tions in deep intronic regions, not covered by the primer design. In this regard, in an attempt to find the second 
mutant allele, we analysed two commonly reported deep intronic mutations: c.2991+1655A>G in CEP29052 
and c.7595−2144A>G in USH2A genes53,54, in patients with heterozygous mutations in those genes. We did not 
however, find the mutations that were likely causative of the disease within these regions.
Despite limitations inherent to NGS sequencing regarding its performance in repetitive or CG-rich regions of 
the genome, we were able to detect the mutation c.2232_2235del in ORF15 of the RPGR gene, a region regarded 
as challenging, with a poor sequencing performance, both in panel based NGS and Whole exome sequencing15. 
Using our methodology we were able to detect this mutation among one of the 16 samples of the pool, which 
further support the validity of our method in terms of sequencing capacity, genotyping and filtering methods 
(Supplementary Fig. S3).
Regarding the mutations found, USH2A represents the most commonly mutated gene within our cohort of 
patients, with eleven different mutations found in this gene in seven patients characterized. Among USH2 genes, 
USH2A is the most commonly mutated gene and it is responsible for approximately 74–90% of USH2 cases8,55,56. 
Mutations in USH2A, are responsible for Usher syndrome type 2 and non-syndromic RP57. CERKL and EYS are 
the next most commonly mutated genes in our cohort, which is also in accordance with previous studies58,59. In 
case of mutations in EYS genes, high prevalence has also been observed among Spanish population14, Americans 
with European origin13 and among Japanese populations60.
For those patients for whom we failed to identify putative disease-causing mutations, the use of alternative 
approaches will hopefully succeed in characterizing their disease, at the molecular level. For instance, WES aimed 
at the identification of mutations in genes not currently linked to IRDs; aCGH arrays for the analysis of CNVa 
in other genes or regions not covered by our MLPA analysis; or whole genome sequencing to extend the analysis 
to the 99% of non-coding DNA. Despite being highly dependent on technical support, the use of whole genome 
sequencing is gaining momentum in clinical practice, and it seems plausible that it will become feasible in a near 
future, once a robust translational genomics workflow becomes an affordable option both in economic and tech-
nical terms, to allow feedback of potentially diagnostic findings to clinicians and research participants61.
Materials and Methods
Study subjects. IRD patients were clinically diagnosed by the Ophthalmology Service at Donostia University 
Hospital, San Sebastian, Spain. Most patients studied had been given a diagnosis of retinitis pigmentosa, though a 
few patients with an undetermined inherited retinal dystrophy (IRD) were also included, based on pedigrees and 
clinical criteria. The inclusion criteria used were night blindness, peripheral visual field loss, pigmentary depos-
its resembling bone spicules, retinal vessels attenuation, optic disc pallor and reduced rod and cone response 
amplitudes and a delay in their timing in the electroretinogram (Hartong, 2006). A total of 115 probands were 
selected. In addition, samples from 13 patients were included as characterized control patients. This control group 
was composed of 8/13 samples selected from our cohort of IRD patients with mutations identified in previous 
studies9,29,35 and a further 5 control samples from IRD patients characterized by a third party laboratory, (those 
for which we were blinded to information regarding mutations until we had completed our analysis). Family ped-
igrees were generated from information obtained from probands. All procedures performed in studies involving 
human participants received approval from the ethical standards of the Clinical Research Ethics Committee of 
the Basque Country, Spain (CEIC-E) and were in accordance with the 2013 Helsinki declaration or comparable 
ethical standards. Informed consent was obtained from all individual participants included in the study.
Human sample collection. High molecular weight DNA was extracted from blood samples from RP 
patients and their available family members. Total DNA from samples was extracted and isolated with the 
AutoGenFlex Star instrument (AutoGen, Holliston, MA, USA) using the FlexiGene DNA Kit (Qiagen, Hilden, 
Germany) following the manufacturer´s instructions. DNA concentrations were measured on the Qubit fluorom-
eter using Quant-iT PicoGreen reagent (Invitrogen, Thermo Fisher Scientific, Waltham, MA, USA). Equimolar 
amounts of DNA samples were pooled (100 ng/ul per sample). For a detailed description of the procedure see29.
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Pooled sequencing. In order to assess the sensitivity and cost-effectiveness of our method we performed a 
first experiment to compare the yield obtained after sequencing pools with increasing number of DNA samples 
and we estimated the differences in costs involved in individual vs. pooled sequencing. All pools were made up 
from samples from carriers of low-frequency variants, which corresponded to either causal, variants of uncertain 
significance (VUS) or non-pathogenic variants identified in previous studies9,29,35. A total of 13 control samples 
were used in 3 sets of pools, with 4, 8 and 16 control samples in each. Of these control samples, 9 carried path-
ogenic variants (one provided by a third party laboratory), while 7 carried low frequency variants with a minor 
allele frequency (MAF) <0.003, and therefore we used these 7 samples both as controls and as test samples. 
Samples were prepared as follows: An initial pool of 4 samples was generated. This pool was used to generate the 3 
pools, adding 0, 4 or 8 more samples to generate the pools with 4, 8 and 16 samples, respectively (Supplementary 
Fig. S1A and Supplementary Table S3A).
In order to further test the sensitivity of our method and to detect possible differences in the sequencing 
yield, inherent to each sequencing run, we conducted a complementary experiment. For this, we used a different 
set of controls, all from carriers of low-frequency, non-disease causing variants or individuals with recessive 
phenotypes with disease causing mutations present in only one allele. In this case, out of 115 patients analysed, 
a total of 108 test samples were interrogated: 16/108 corresponded to carriers of a total of 21 previously detected 
non disease causing variants with low MAF (<0.003) and were, therefore, used as both control and test samples 
(Supplementary Table S3B). 53/108 samples corresponded to patients that had been interrogated previously with 
negative results, and 39/108 corresponded to new samples interrogated in this study for the first time. As addi-
tional controls we used four samples from carriers of disease causing mutations provided by a third party labo-
ratory (for which we were blinded to mutation-related information until after our analysis). For this experiment, 
patients were divided into 7 pools with 16 samples each. Control samples were distributed among each pool such 
as that each pool contained at least 2 control samples, and 4/7 pools had also control from a third party laboratory 
(Supplementary Fig. S1B).
Amplicon Library preparation. Ion AmpliSeq Library Preparation Kit v2.0 (Thermo Fisher Scientific) 
was used to construct an amplicon library from genomic target regions with a maximum read length of approx-
imately 200 base pairs (average length, 142 bp) for shotgun sequencing on an Ion Proton system (Thermo Fisher 
Scientific). Briefly, target genomic regions were amplified by simple PCR using Ion Ampliseq primer pools and 
10 ng of each DNA samples.
Sequencing Analysis. Ion Proton Sequencing. NGS was carried out on the Ion Proton system (Thermo 
Fisher Scientific). Briefly, enriched ion sphere particles (ISPs) were annealed with the sequencing primer and 
mixed with the sequencing polymerase from the Ion PGM_200 Sequencing Kit (Thermo Fisher Scientific). Then, 
the polymerase-bound and primer-activated ISPs were loaded into the previously checked and washed Ion PI 
Chips (Life Technologies) and having planned the run on the Ion Proton System software, chips were subjected 
to 500 cycles of sequencing with the standard nucleotide flow order. Signal processing and base calling of data 
generated from the Ion Proton runs were performed with the Ion Torrent platform-specific analysis software 
(Torrent Suite version 4.0).
Variant calling. Using the Ion Reporter software we performed the variant calling. First of all GRCh37/hg19 was 
used as reference genome and alignment was performed against a bed file containing all regions corresponding to 
316 genes sequenced. A key aspect in our mutation detection pipeline was to take into consideration the dilution 
effect of each variant due to our pooled sequencing approach. Therefore we used the pipeline provided by the ion 
reporter program for the detection of somatic mutations with minor modifications. We used a somatic mutation 
detection approach, since this is the most suited for the detection of variants represented in very low frequency (1 in 
32 alleles, in the lowest case). The only modification to the default parameters provided by the ion reporter program 
(5.0 version) consisted on the switch of 10 parameters within the Variant Filtering section in Parameters tab. All 
parameters are described in detail in Supplementary Table S5. Finally, a Variant Caller File (VCF) was generated.
Genotyping by high resolution melting (HRM) analysis. Likely disease causing variants from each 
pool of 16 samples were selected from the VCF. Specific primers were designed to perform a HRM analysis gener-
ating amplicons ranging between 250 to 330 bp in length, in order to cover the mutation position. HRM analysis 
was used to identify which sample/s among 16 in the pool carried the mutation. We followed the methodology 
described in29, with minor modification. Briefly, PCR amplification and HRM were performed in a single run on 
a 7900HT Fast Real-Time PCR System in 384-well plates (Applied Biosystems), each plate contained individual 
samples (in triplicates) from the 16 probands of the pool in which the variant was detected. We analysed up to 7 
different variants in parallel in a single run. After HRM run, the analysis of post amplification fluorescent melting 
curves was performed using the HRM V2.0.1 software (ThermoFisher Scientific). Melting curves were normal-
ized and difference plots were generated to compare the samples. Only samples showing a different melting curve 
(Fig. 2) were Sanger sequenced.
Sanger sequencing. Sanger sequencing was used to confirm those mutations detected by NGS and for 
co-segregation analysis using a 16-capillary ABI 3130xl platform (Applied Biosystems, Foster City, CA, USA) 
according to manufacturer´s protocol. Sequences were analysed and compared with wild-type samples and a ref-
erence sequences using BioEdit software (Ibis Biosciences, Carlsbad, CA, USA) and Ensembl and NCBI databases.
Relevant variant priorization and pathogenicity score. In order to determine genomic variants of 
relevance, we selected the potential disease causing variants according to the following pre-established criteria:
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 (1) Variants previously reported as pathogenic.
 (2) Variants with a MAF <0.001 for dominant genes or MAF <0.003 for recessive genes obtained from ge-
nome aggregation database (gnomAD).
 (3) Novel Splicing variants and loss-of-function variants such as nonsense mutations, frameshift deletions or 
insertions.
 (4) Previously reported missense variants with pathogenicity scores assessed by in silico predictive software.
 (5) Novel missense variants predicted to be damaging by in-silico predictive software (as mentioned below).
Presence for all candidate variants was checked using the Spanish Variant Server Database (CSVS), (http://
csvs.babelomics.org/)62. For dominant variants, only those absent from this database were considered further. 
With regard to recessive variants, only those variants with a MAF lower than 0.003 and only present in heterozy-
gosis were considered further.
Multiplex Ligation-dependent Probe Amplification assay (MLPA). MLPA was used to search for 
genomic copy number variations in 32 patients without causative mutations found after sequencing of 316 IRD 
genes. We selected 9 genes with high prevalence of reported rearrangements38–40.
Patients with a dominant inheritance pattern were analysed using MLPA Retinitis Probemix (P235). This 
probemix contains PRPF31, RHO, RP1 and IMPDH1 genes.
Patients with heterozygotic mutations in USH2A genes or EYS were also analysed for CNVs, in search of the 
second mutated allele within these genes (Salsa Mixes P361/2 and P328, respectively).
In addition, patients with an X-linked inheritance pattern, clinically diagnosed with choroideremia or families 
with only males affected, were analysed for RP2, RPGR and CHM genes (Salsa probemix P366).
MLPA reactions were run according to the manufacturer’s general recommendations (MRC-Holland, 
Amsterdam, Holland) as previously described63. The MLPA reaction products were separated by capillary elec-
trophoresis on Abi Prism 3130XL Analyzer (Applied Biosystems) and the results obtained were analysed by 
GeneMapper software (Thermo Fisher Scientific).
Pathogenicity predictive software. SIFT (http://www.sift.bii.a-star.edu.sg).
Polyphen2 (http://www.genetics.bwh.harvard.edu/pph2/).
PROVEAN (http://provean.jcvi.org/seq_submit.php)64.
GVGD (agvgd.iarc.fr/agvgd_input_php)65.
MutationTaster (www.mutationtaster.org)66.
Web sources. Ensembl, http://www.ensembl.org/.
NCBI, http://www.ncbi.nlm.nih.gov/.
Polyphen-2, http://www.genetics.bwh.harvard.edu/pph2/.
RetNet, http://www.sph.uth.tmc.edu/Retnet/.
SIFT, http://www.sift.bii.a-star.edu.sg/.
SNPnexus, http://www.snp-nexus.org/.
The Human Genome Variation Society (HGVS), http://www.hgvs.org/.
1000 Genomes, http://www.1000genomes.org/_ENREF_48.
NHLBI Exome Sequencing Project (ESP), http://evs.gs.washington.edu/EVS/.
Babelomics, http://csvs.babelomics.org.
ExacBrowse, http://exac.broadinstitute.org/.
GnomAD browser, http://gnomad.broadinstitute.org/.
Figure 2. HRM analysis of TULP1 gene. Difference plot shows c.1495+1G>C mutation in TULP1 gene, with 2 
out of 16 samples that clearly differ from the non-carrier samples (grey lines). Sanger sequencing confirmed the 
presence of the mutation c.1495+1G>C in two patients, one in heterozygosis (blue lines) and the other one in 
homozygosis (red lines). Note that samples are in triplicates.
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